Overcoming Treatment Access Barriers in EoE

This episode, titled ‘Overcoming Treatment Access Barriers in EoE,’ features panelists discussing system-level challenges that can affect timely access to treatment and monitoring for patients with eosinophilic esophagitis. The expert faculty examine how insurance requirements, prior authorization processes, medication costs, and coverage limitations can delay treatment initiation or create additional burdens for patients navigating long-term EoE care.

The panelists share practical approaches they use to anticipate and address these barriers in clinical practice. They highlight the value of involving clinical pharmacy and administrative teams early in the treatment process to facilitate prior authorizations and reduce unnecessary delays. Clear and comprehensive documentation is also emphasized, particularly when communicating the rationale for a selected therapy, previous treatment history, and relevant endoscopic and histologic findings to insurers.

Beyond medication access, the panel discusses financial barriers associated with ongoing disease monitoring. They describe situations in which insurance coverage or patient costs may limit access to repeat endoscopy, creating challenges when clinicians need objective measures to assess treatment response and disease control. The panelists also emphasize transparency with patients about potential delays and out-of-pocket costs so expectations can be established early in the treatment process. Finally, the expert faculty discuss available resources that may help patients navigate affordability concerns, including copay support and patient assistance programs. Throughout the episode, the panel underscores the importance of a coordinated, team-based approach involving clinicians, pharmacists, administrative staff, and patients to navigate access barriers and help patients receive appropriate EoE treatment and follow-up care.

In the next episode, ‘Emerging Therapies and the Future of EoE Care,’ panelists will explore investigational therapies that may expand the EoE treatment landscape and enable increasingly individualized care. They also reflect on key takeaways from the series, emphasizing comprehensive disease assessment, long-term management, and clinician-patient partnership.